 Each volunteer will be involved in the study for 180 days. Participants in Cohort 1 will be randomly assigned to receive LGTTP21DEN4 or placebo at study entry. Cohort 2 will begin only after safety review of all participants in Cohort 1. Participants in Cohort 2 will receive a higher dose of LGTTP21DEN4 or placebo. 